Monday, 16 Sep 2019

You are here

Steroid Sparing Effects of Methotrexate and Mycophenolate in Uveitis

Patients with noninfectious uveitis (intermediate, posterior uveitis, or panuveitis) often require high dose corticosteroids and therefore may need steroid-sparing DMARD therapy. The FAST study investigated the corticosteroid-sparing effect of methotrexate or mycophenolate mofetil in adults with noninfectious uveitis.

The First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial enrolled 216 patients with active noninfectious intermediate uveitis, posterior uveitis, and panuveitis and they were randomized to either oral methotrexate, 25 mg weekly (n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109). The primary outcome was treatment success at 6 months, which was defined as having control of inflammation in both eyes, no more than 7.5 mg prednisone daily and less than or equal to 2 drops of prednisolone acetate 1%, and no treatment failure after 12 mos.

With nearly 90% of patients completing follow-up through 6 months, treatment success was seen in 66.7% of methotrexate group compared with 57.1% in the mycophenolate group, a difference that was not statistically significant.

However, in those with posterior uveitis or panuveitis, treatment success was achieved in 74% on methotrexate versus 55% on mycophenolate (P = .02).

Intermediate uveitis was more likely to respond to mycophenolate (64%) compared to methotrexate (33.3%) treated patients (P = .07; P for interaction = .004).

Elevated liver enzymes were the most common nonserious laboratory adverse event, occurring in 14 patients (13.0%) in the methotrexate group and 8 patients (7.4%) in the mycophenolate group.

JAMA reports that both mycophenolate and MTX demonstrated steroid sparing effects in the majority of patients.  While there were no overall differences in treatment success (efficacy plus corticosteroid-sparing) intermediate uveitis tended to respond better to mycophenolate, while posterior and panuveitis responded better to MTX.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Vitamin D Supplements Fail to Prevent Type 2 Diabetes - DUH!

A NEJM report shows that the use of vitamin D3 supplementation (4000 IU per day) in those without diabetes or vitamin D deficiency failed to significantly lower risk of type 2 diabetes (compared to placebo).

The rational for this report included observational data showing an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes.

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants

The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.

Rituximab Superior to Cyclosporine for Membranous Nephropathy

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.